Breaking News

Why Biogen’s Medicare mess is bad for the pharmaceutical industry

Why Biogen’s Medicare mess is bad for the pharmaceutical industry


Medicare’s proposal that it will deal with Alzheimer’s medicines these kinds of as Biogen’s embattled Aduhelm only in scientific trials could have a straightforward but tricky result for the pharmaceutical field: chaos.

The draft choice introduced yesterday is a reaction to the June decision by the Food and Drug Administration to grant the drugs an accelerated acceptance, likely against a committee of the FDA’s skilled advisers. That sets up an strange dynamic: Normally, Medicare, the government’s health benefit for men and women 65 and more mature, handles medications as soon as the Fda approves them. For some medications, it is required to do so. But in this circumstance, Medicare is trying to put a genie again in the bottle, requiring that Biogen and other drug makers do reports that were not expected by the Fda before Medicare will concur to cover Alzheimer’s medicine.

Unlock this posting by subscribing to STAT+ and enjoy your 1st 30 days absolutely free!

GET Started out





Resource hyperlink